CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps

Launched by BEIJING TONGREN HOSPITAL · Oct 25, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a specific protein called CST1 to see how well it can predict how patients with chronic rhinosinusitis and nasal polyps will respond to oral glucocorticoid therapy, which are medications used to reduce inflammation. The study is focused on adults aged 18 to 70 who have been diagnosed with chronic rhinosinusitis with nasal polyps and have a certain level of polyp severity. Researchers will evaluate various symptoms and scores measuring nasal issues before and after treatment to understand the relationship between CST1 levels and treatment response.

Participants in this study can expect to undergo assessments that include checking the size of their nasal polyps and how their symptoms improve after taking the medication. However, individuals with certain health conditions, like diabetes or recent infections, or those who have used specific medications recently, will not be eligible to join the trial. This research aims to help doctors better predict which patients will benefit most from glucocorticoid treatments, ultimately improving care for those with chronic rhinosinusitis and nasal polyps.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All meet the diagnostic criteria of CRSwNP in EPOS2020 (Age 18-70 years old);
• • 2. Investigator-assessed endoscopic bilateral Nasal Polyp Size Score (NPSS) was greater than or equal to 4 (minimum score of 2 per nasal cavity);
• Exclusion Criteria:
• • 1. Oral glucocorticoid contraindications, such as diabetes, femoral head necrosis, gastric ulcer, etc.
• • 2. Medication history of oral glucocorticoids or immunomodulator within 1 months before enrollment, antibiotics within 2 weeks;
• • 3. fungal sinusitis, allergic fungal sinusitis (AFRS), cystic fibrosis, primary ciliary dyskinesia